Impact of Acamprosate on Chronic Tinnitus: A Randomized-Controlled Trial

Discussion in 'Research News' started by Tigo, Jun 12, 2020.

    1. Tigo

      Tigo Member

      Tinnitus Since:
      2 years
      Cause of Tinnitus:
      genetic hearing loss
      Impact of Acamprosate on Chronic Tinnitus: A Randomized-Controlled Trial

      Objectives: Tinnitus is a common and distressing otologic symptom, with various probable pathophysiologic mechanisms, such as an imbalance between excitatory and inhibitory mechanisms. Acamprosate, generally used to treat alcoholism, is a glutaminergic antagonist and GABA agonist suggested for treating tinnitus. Thus, we aimed to evaluate the efficacy and safety of acamprosate in the treatment of tinnitus.

      Methods: The current randomized-controlled trial study included 20 subjects with chronic tinnitus. After performing psycho-acoustic, psychometric and electrophysiological evaluations, all studied tinnitus subjects were randomly divided into two groups of acamprosate and placebo. The first group received oral acamprosate (two tablets of 333 mg/d, three times a day), whereas the second group was given placebo treatment (two tablets, three times a day). After the first 30 days, all evaluations were repeated for the studied groups just in the same manner before the study. Subsequently, the final results of each evaluation were compared together with the baseline values.

      Results: Nine studied subjects randomly received acamprosate, whereas eleven others received a placebo. There was no significant improvement in the psycho-acoustic tests, except a decrease was observed in the pitch match of tinnitus (P = .039). For those subjects who were receiving acamprosate, a significant reduction was observed in tinnitus handicap inventory (P = .006), tinnitus questionnaire scores (P = .007), and the visual analog scores (P = .007) compared to the placebo group. There was a significant reduction in Action Potential latency (P = .048) as well as an increase in the amplitude of distortion product otoacoustic emissions at 4 kHz (P = .048).

      Conclusions: The study results indicated a subjective relief of tinnitus as well as some degree of the electrophysiological improvement at the level of the cochlear and the distal portion of the auditory nerve among the subjects who received the acamprosate.

      • Like Like x 1
      • Informative Informative x 1
    2. Pre55ure

      Pre55ure Member

      Tinnitus Since:
      May 2019
      Cause of Tinnitus:
      Cochlear migraines
      I have now looked up 2 additional studies that also found that acamprosate seemed to lower tinnitus levels while being relatively safe. Is there something I am missing here? Is there some reason that this isn't being prescribed (even off label)? This is the first I have ever heard of it.
      • Good Question Good Question x 1
    3. Croaker

      Croaker Member Benefactor

      Tinnitus Since:
      01/2019 T, 04/2020 H
      Cause of Tinnitus:
      Headphones/Car Alarm/Immune Response?
      Iā€™m no expert but it looks like just another gaba inhibitor.... this was a popular research path a while back but it never seemed to pan out in more rigorous studies.

Share This Page